---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-013255"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:48:29.382304+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma raises $10M in registered direct offering of common stock and warrants

## Summary
- Sold 33,333,334 shares and warrants at $0.30/unit; gross proceeds ~$10M.
- Warrants exercisable at $0.35/share for 5.5 years from issuance, starting 6 months post-closing.
- Proceeds to be used for working capital and general corporate purposes.
- Offering expected to close April 5, 2024; A.G.P./Alliance Global Partners sole placement agent.
- Directors and officers subject to 90-day lock-up on securities transfers.

## SEC filing metadata
- accession: 0001493152-24-013255
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/0001493152-24-013255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-013255
- JSON: https://secwatch.observer/filing/0001493152-24-013255.json
- Plain text: https://secwatch.observer/filing/0001493152-24-013255.txt

## Key facts
- Material Agreements
  Matinas BioPharma Holdings, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Placement agent to use reasonable best efforts to sell securities; cash fee of 7.0% of aggregate pur (effective 2024-04-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: Placement agent to use reasonable best efforts to sell securities; cash fee of 7.0% of aggregate pur
  - Effective: 2024-04-02
  source text: On April 2, 2024, the Company also entered into a placement agent agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/0001493152-24-013255-index.htm
- Material Agreements
  Matinas BioPharma Holdings, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at 33,333,334 shares of common stock and warrants to purchase 33,333,334 shares of common stock at offe (effective 2024-04-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: 33,333,334 shares of common stock and warrants to purchase 33,333,334 shares of common stock at offe
  - Effective: 2024-04-02
  source text: On April 2, 2024, Matinas BioPharma Holdings, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/0001493152-24-013255-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.